Consensus guidelines for the management and treatment of neuroendocrine tumors

Pamela L. Kunz, Diane Reidy-Lagunes, Lowell B. Anthony, Erin M. Bertino, Kari Brendtro, Jennifer A. Chan, Herbert Chen, Robert T. Jensen, Michelle Kang Kim, David S. Klimstra, Matthew H. Kulke, Eric H. Liu, David C. Metz, Alexandria T. Phan, Rebecca S. Sippel, Jonathan R. Strosberg, James C. Yao

Research output: Contribution to journalArticlepeer-review

472 Scopus citations


ABSTRACT: Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. The recent completion of several phase 3 trials, including those evaluating octreotide, sunitinib, and everolimus, demonstrate that rigorous evaluation of novel agents in this disease is possible and can lead to practice-changing outcomes. Nevertheless, there are many aspects to the treatment of neuroendocrine tumors that remain unclear and controversial. The North American Neuroendocrine Tumor Society published a set of consensus guidelines in 2010, which provided an overview for the treatment of patients with these malignancies. Here, we present a set of consensus tables intended to complement these guidelines and serve as a quick, accessible reference for the practicing physician.

Original languageEnglish (US)
Pages (from-to)557-577
Number of pages21
Issue number4
StatePublished - May 2013


  • carcinoid
  • neuroendocrine tumors
  • neuroendocrine/diagnosis
  • neuroendocrine/pathology
  • neuroendocrine/treatment
  • pheochromocytoma

ASJC Scopus subject areas

  • Hepatology
  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Consensus guidelines for the management and treatment of neuroendocrine tumors'. Together they form a unique fingerprint.

Cite this